

# Gerardo Musuraca

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8113219/gerardo-musuraca-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

1,357  
citations

17  
h-index

36  
g-index

55  
ext. papers

1,570  
ext. citations

5.1  
avg, IF

3.39  
L-index

#	Paper	IF	Citations
52	Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4293-7	2.2	244
51	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 59-67	27.4	223
50	Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1781-7	2.2	143
49	Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. <i>Cancer</i> , <b>2004</b> , 100, 2190-4	6.4	76
48	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , <b>2008</b> , 9, 352-8	21.7	73
47	Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. <i>Haematologica</i> , <b>2007</b> , 92, 771-7	6.6	65
46	Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. <i>Cancer</i> , <b>2008</b> , 113, 2496-503	6.4	62
45	Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients. <i>Leukemia and Lymphoma</i> , <b>2003</b> , 44, 821-4	1.9	57
44	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , <b>2008</b> , 112, 856-62	6.4	41
43	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. <i>Haematologica</i> , <b>2005</b> , 90, 341-7	6.6	40
42	Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 7, 291-5		36
41	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , <b>2015</b> , 100, 511-6	6.6	34
40	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the. <i>Haematologica</i> , <b>2018</b> , 103, 1345-1350	6.6	26
39	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , <b>2018</b> , 103, 1209-1217	6.6	24
38	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1214-1222	2.2	21
37	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , <b>2018</b> , 36, 68-75	1.3	20
36	Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 172	8.5	17

35	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , <b>2016</b> , 60, 154-65	7.5	16
34	IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 229	8.5	13
33	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. <i>Cancer</i> , <b>2010</b> , 116, 5667-75	6.4	13
32	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	12
31	Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 124-126	19.7	10
30	VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 2167-71	1.9	9
29	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 37-40	3.6	9
28	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 63	7	9
27	The emerging role of GSK-3 $\beta$ in the pathobiology of classical Hodgkin lymphoma. <i>Histopathology</i> , <b>2017</b> , 71, 72-80	7.3	7
26	Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 1437-40	1.9	6
25	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly ( $\geq 70$ years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2890-2898	1.9	5
24	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
23	The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 548-558	4.3	4
22	Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 1839-41	1.9	4
21	High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 321-6	1.9	4
20	Phase II Study of Proteasome Inhibitor Bortezomib (Velcade $\text{\textregistered}$ ) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.. <i>Blood</i> , <b>2006</b> , 108, 2462-2462	2.2	4
19	CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
18	Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). <i>American Journal of Hematology</i> , <b>2011</b> , 86, 79-80	7.1	3

17	Pentoxifylline-Induced Apoptosis in Chronic Lymphocytic Leukemia: New Insights into Molecular Mechanism. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2018</b> , 18, 287-294	3.2	3
16	A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. <i>Blood</i> , <b>2006</b> , 108, 2431-2431	2.2	2
15	Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 335-338	4.5	2
14	Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. <i>Blood Advances</i> , <b>2020</b> , 4, 5040-5049	7.8	2
13	Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report. <i>Annals of Hematology</i> , <b>2015</b> , 94, 1597-8	3	1
12	Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. <i>Blood</i> , <b>2021</b> , 138, 134-134	2.2	1
11	Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. <i>Oncology Reports</i> , <b>2020</b> , 44, 1561-1573	3.5	1
10	Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report. <i>Medicine (United States)</i> , <b>2020</b> , 99, e21440	1.8	1
9	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. <i>Cell Biology and Toxicology</i> , <b>2021</b> , 1	7.4	1
8	Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , <b>2021</b> , 138, 48-48	2.2	0
7	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study VeritasT <i>Blood</i> , <b>2020</b> , 136, 47-49	2.2	
6	IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	
5	Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL AgentsTera. <i>Blood</i> , <b>2020</b> , 136, 2-3	2.2	
4	Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Blood</i> , <b>2020</b> , 136, 18-18	2.2	
3	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 1-1	2.2	
2	A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , <b>2021</b>	2.2	
1	A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.. <i>Blood</i> , <b>2006</b> , 108, 2478-2478	2.2	